Compare Amcor PLC (AMCR) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Amcor PLC trades at $46.93 (market cap $21.92B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.09 (market cap $9.43B). The key difference: Amcor PLC is far larger — about 2.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Amcor PLC pays a 5.49% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| AMCR | BIO | |
|---|---|---|
Market Cap | $21.92B | $9.43B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $356.25 |
52-Week Low | $36.69 | $241.71 |
Enterprise Value | $37.03B | $9.18B |
Dividend Yield | 5.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $46.85, down 0.55% today, with a bullish technical outlook supported by moving averages and strong earnings beats in the last four quarters. The company reported Q2 2026 EPS of $1.23, exceeding estimates, and maintains a 64% analyst buy rating with a $47.00 consensus target. Recent news highlights expansion in China and strong Q4 results, though net income margin declined to 3.06% in 2025.
The stock presents a balanced opportunity with solid earnings performance and analyst support, but risks include elevated P/E of 38.07, margin pressure, and high debt levels. Upside is capped near-term by technical resistance at $48, while support lies at $46.
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
